Enterocolitis - Pipeline Review, H2 2019
Enterocolitis - Pipeline Review, H2 2019
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Enterocolitis - Pipeline Review, H2 2019, provides an overview of the Enterocolitis (Gastrointestinal) pipeline landscape.
Enterocolitis is an inflammation of the large and small intestines. Symptoms include fever, abdominal swelling, nausea, diarrhea, rectal bleeding and sluggishness. Causes of enterocolitis include Inflammation of the intestinal tissues, delayed gastric emptying, abdominal wall erythema, apnea, sepsis and cardiovascular collapse. Treatment includes antibiotics.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Enterocolitis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Enterocolitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Enterocolitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Enterocolitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 1 and 9 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Enterocolitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Enterocolitis - Pipeline Review, H2 2019, provides an overview of the Enterocolitis (Gastrointestinal) pipeline landscape.
Enterocolitis is an inflammation of the large and small intestines. Symptoms include fever, abdominal swelling, nausea, diarrhea, rectal bleeding and sluggishness. Causes of enterocolitis include Inflammation of the intestinal tissues, delayed gastric emptying, abdominal wall erythema, apnea, sepsis and cardiovascular collapse. Treatment includes antibiotics.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Enterocolitis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Enterocolitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Enterocolitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Enterocolitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 1 and 9 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Enterocolitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Enterocolitis (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Enterocolitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Enterocolitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Enterocolitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Enterocolitis (Gastrointestinal)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Enterocolitis (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Enterocolitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Enterocolitis - Overview
Enterocolitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Enterocolitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Enterocolitis - Companies Involved in Therapeutics Development
Avexegen Therapeutics Inc
Glycohub Inc
Glycosyn LLC
Infant Bacterial Therapeutics AB
Leadiant Biosciences Inc
Liminal BioSciences Inc
Noveome Biotherapeutics Inc
Plakous Therapeutics Inc
Scioto Biosciences Inc
Synthetic Biologics Inc
Worphmed Srl
Enterocolitis - Drug Profiles
alpha-1 proteinase inhibitor (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C-34 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IBP-9414 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
melatonin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NRG-4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PROTEGO-PD - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SB-121 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Infectious Diarrhea and Necrotizing Enterocolitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Necrotizing Enterocolitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ST-266 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
STP-206 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SYN-020 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Enterocolitis - Dormant Projects
Enterocolitis - Product Development Milestones
Featured News & Press Releases
Jul 05, 2019: Infant Bacterial enrols first patient in NEC study
May 19, 2019: FDA and Infant Bacterial Therapeutics agree on the design of Phase III study
Mar 05, 2019: Infant Bacterial Therapeutics announces first distribution agreement
Nov 21, 2018: The Phase 3 study protocol is modified after IBT's meeting with the FDA
Nov 09, 2018: IBTs Chief Scientific Officer invited to speak at NEC Society Symposium 2019
May 15, 2018: Infant Bacterial Therapeutics: Interim Management Statement, January 1 - March 31, 2018
Mar 05, 2018: Prometic receives Rare Pediatric Disease Designation from U.S. FDA for its Inter-Alpha-Inhibitor-Proteins
Feb 15, 2018: Prometic granted orphan drug designation by FDA for Inter-Alpha-Inhibitor-Proteins for treatment of necrotizing enterocolitis (NEC)
Dec 11, 2017: Infant Bacterial Therapeutics presents data from its Safety and Tolerability Study in premature infants
Nov 23, 2017: Infant Bacterial Therapeutics Interim Management Statement, January 1 - September 29, 2017
Sep 28, 2017: European Medicines Agency adopts a positive opinion on the Paediatric Investigation Plan for IBT’s lead product
Sep 11, 2017: Infant Bacterial Therapeutics announces that top line data demonstrate similar safety and tolerability profile in the active and placebo groups
Jan 24, 2017: Last patient enrolled in IBT's Phase 2 study
Nov 21, 2016: Positive recommendation from the independent Data Safety Monitoring Board to continue Phase II Study
Jun 07, 2016: Infant Bacterial Therapeutics enrolls First Patient in Phase 2 Clinical Trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Enterocolitis - Overview
Enterocolitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Enterocolitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Enterocolitis - Companies Involved in Therapeutics Development
Avexegen Therapeutics Inc
Glycohub Inc
Glycosyn LLC
Infant Bacterial Therapeutics AB
Leadiant Biosciences Inc
Liminal BioSciences Inc
Noveome Biotherapeutics Inc
Plakous Therapeutics Inc
Scioto Biosciences Inc
Synthetic Biologics Inc
Worphmed Srl
Enterocolitis - Drug Profiles
alpha-1 proteinase inhibitor (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C-34 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IBP-9414 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
melatonin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NRG-4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PROTEGO-PD - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SB-121 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Infectious Diarrhea and Necrotizing Enterocolitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Necrotizing Enterocolitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ST-266 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
STP-206 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SYN-020 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Enterocolitis - Dormant Projects
Enterocolitis - Product Development Milestones
Featured News & Press Releases
Jul 05, 2019: Infant Bacterial enrols first patient in NEC study
May 19, 2019: FDA and Infant Bacterial Therapeutics agree on the design of Phase III study
Mar 05, 2019: Infant Bacterial Therapeutics announces first distribution agreement
Nov 21, 2018: The Phase 3 study protocol is modified after IBT's meeting with the FDA
Nov 09, 2018: IBTs Chief Scientific Officer invited to speak at NEC Society Symposium 2019
May 15, 2018: Infant Bacterial Therapeutics: Interim Management Statement, January 1 - March 31, 2018
Mar 05, 2018: Prometic receives Rare Pediatric Disease Designation from U.S. FDA for its Inter-Alpha-Inhibitor-Proteins
Feb 15, 2018: Prometic granted orphan drug designation by FDA for Inter-Alpha-Inhibitor-Proteins for treatment of necrotizing enterocolitis (NEC)
Dec 11, 2017: Infant Bacterial Therapeutics presents data from its Safety and Tolerability Study in premature infants
Nov 23, 2017: Infant Bacterial Therapeutics Interim Management Statement, January 1 - September 29, 2017
Sep 28, 2017: European Medicines Agency adopts a positive opinion on the Paediatric Investigation Plan for IBT’s lead product
Sep 11, 2017: Infant Bacterial Therapeutics announces that top line data demonstrate similar safety and tolerability profile in the active and placebo groups
Jan 24, 2017: Last patient enrolled in IBT's Phase 2 study
Nov 21, 2016: Positive recommendation from the independent Data Safety Monitoring Board to continue Phase II Study
Jun 07, 2016: Infant Bacterial Therapeutics enrolls First Patient in Phase 2 Clinical Trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Enterocolitis, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Enterocolitis - Pipeline by Avexegen Therapeutics Inc, H2 2019
Enterocolitis - Pipeline by Glycohub Inc, H2 2019
Enterocolitis - Pipeline by Glycosyn LLC, H2 2019
Enterocolitis - Pipeline by Infant Bacterial Therapeutics AB, H2 2019
Enterocolitis - Pipeline by Leadiant Biosciences Inc, H2 2019
Enterocolitis - Pipeline by Liminal BioSciences Inc, H2 2019
Enterocolitis - Pipeline by Noveome Biotherapeutics Inc, H2 2019
Enterocolitis - Pipeline by Plakous Therapeutics Inc, H2 2019
Enterocolitis - Pipeline by Scioto Biosciences Inc, H2 2019
Enterocolitis - Pipeline by Synthetic Biologics Inc, H2 2019
Enterocolitis - Pipeline by Worphmed Srl, H2 2019
Enterocolitis - Dormant Projects, H2 2019
Number of Products under Development for Enterocolitis, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Enterocolitis - Pipeline by Avexegen Therapeutics Inc, H2 2019
Enterocolitis - Pipeline by Glycohub Inc, H2 2019
Enterocolitis - Pipeline by Glycosyn LLC, H2 2019
Enterocolitis - Pipeline by Infant Bacterial Therapeutics AB, H2 2019
Enterocolitis - Pipeline by Leadiant Biosciences Inc, H2 2019
Enterocolitis - Pipeline by Liminal BioSciences Inc, H2 2019
Enterocolitis - Pipeline by Noveome Biotherapeutics Inc, H2 2019
Enterocolitis - Pipeline by Plakous Therapeutics Inc, H2 2019
Enterocolitis - Pipeline by Scioto Biosciences Inc, H2 2019
Enterocolitis - Pipeline by Synthetic Biologics Inc, H2 2019
Enterocolitis - Pipeline by Worphmed Srl, H2 2019
Enterocolitis - Dormant Projects, H2 2019
LIST OF FIGURES
Number of Products under Development for Enterocolitis, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Targets, H2 2019
Number of Products by Stage and Targets, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
Avexegen Therapeutics Inc
Glycohub Inc
Glycosyn LLC
Infant Bacterial Therapeutics AB
Leadiant Biosciences Inc
Liminal BioSciences Inc
Noveome Biotherapeutics Inc
Plakous Therapeutics Inc
Scioto Biosciences Inc
Synthetic Biologics Inc
Worphmed Srl
Number of Products under Development for Enterocolitis, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Targets, H2 2019
Number of Products by Stage and Targets, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
Avexegen Therapeutics Inc
Glycohub Inc
Glycosyn LLC
Infant Bacterial Therapeutics AB
Leadiant Biosciences Inc
Liminal BioSciences Inc
Noveome Biotherapeutics Inc
Plakous Therapeutics Inc
Scioto Biosciences Inc
Synthetic Biologics Inc
Worphmed Srl
